NCT07058337

Methotrexate in Retinal Detachment With Proliferative Vitreoretinopathy

Methotrexate as an Adjunct to Parsplana Vitrectomy for the Preventing and Treatment of Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment: A Clinical Study

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Benha University · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The aim of this study is to evaluate the efficacy and safety of intraocular methotrexate (MTX) in preventing and managing proliferative vitreoretinopathy (PVR) in patients undergoing retinal detachment surgery

Detailed description

Patients will be randomized into two groups if clinical evidence of PVR is detected at the time of surgery, utilizing a computer-generated list for randomization. All surgeries will be conducted by the same surgeon to maintain consistency in technique. Intervention Groups: 1\. Group 1 (PPV Alone): Patients in this group will undergo pars plana vitrectomy (PPV) only. Group 2 (PPV with Methotrexate): Patients in this group will receive complete PPV along with adjunctive intravitreal methotrexate.

Conditions

• Retinal Detachment

Interventions

Type	Name	Description
PROCEDURE	parsplana vitrectomy	23 gauge parsplana vitrectomy
PROCEDURE	adjunctive use of Methotrexate	intravitreal methotrexate (200 μg/0.05 ml) at the time of surgery and repeated weekly for four weeks postoperatively

Timeline

• Start date: 2024-06-09
• Primary completion: 2025-06-01
• Completion: 2025-06-09
• First posted: 2025-07-10
• Last updated: 2025-07-10

Locations

1 site across 1 country: Egypt